India HbA1c Market is predicted to reach USD 0.29 billion at a CAGR of 8.49% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global India HbA1c Market”.

The India HbA1c market is projected to register a CAGR of 8.49% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the India HbA1c market are Siemens Healthineers AG (Germany), PTS Diagnostics (US), ARKRAY, Inc (Japan), Abbott (US), Bio-Rad Laboratories, Inc (US), Transasia Bio-Medicals (India), F. Hoffmann-La Roche Ltd. (Switzerland), Beckman Coulter, Inc. (US), LumiraDx (UK), and HemoCue AB (Sweden).

India HbA1c Market Highlights

The India HbA1c market is accounted to register a CAGR of 8.49% during the forecast period and is estimated to reach USD 0.29 billion by 2032.

Increasing demand for HbA1c testing is due to increasing incidences of type 2 diabetes among the Indian population driving the growth of market. For instance, in November 2021, as per the World Health Organization, there were an estimated 77 million people suffering from type 2 diabetes, especially those over the age of 18.

Furthermore, the increased prevalence of thalassemia and sickle cell diseases among the population in India is driving the growth of the HBa1c test market in the country. Thalassemia and sickle cell diseases are genetic blood disorders that affect the production of hemoglobin, a protein found in red blood cells. Individuals with these conditions often have abnormal levels of hemoglobin, which can lead to various health complications. The HBa1c test, also known as glycated hemoglobin test, is a widely used diagnostic tool to measure average blood sugar levels over a period of time. It is primarily used in the diagnosis and management of diabetes. However, in the case of thalassemia and sickle cell diseases, the HBa1c test can also be used to monitor the effectiveness of treatment and assess the risk of complications. Since individuals with these conditions often have abnormal hemoglobin levels, the HBa1c test provides valuable information about their overall blood sugar control.

However, the high cost of HbA1c testing is a significant barrier to its wider adoption and effective diabetes management, particularly for individuals with limited financial resources. There are several factors affecting the increasing cost of HbA1c testing, such as technological advancements, because developing and maintaining the technology behind accurate HbA1c testing requires research, investment, and specialized equipment, which add to the increase in cost. Moreover, the process of analyzing blood samples for HbA1c involves trained personnel, specific reagents, and quality control measures, contributing to the testing cost. As per secondary sources, including laboratories and hospitals of India, the price range for HbA1c testing falls between USD 3.49 and 9.03, and prices may vary based on tier one, tier two, and tier three cities. Moreover, if a patient is suffering from type 2 diabetes and the condition seems moderately worse, then they have to go for a test twice a month or once a month, and this may be costly for low- and middle-income patients if it adds up to a year. Therefore, the high cost of HbA1c testing is restraining the growth of the market.

Additionally, growing geriatric population across the country is major opportunity for the key players operating in the market. As, the geriatric population tends to have a higher prevalence of chronic diseases such as diabetes, which require regular monitoring of blood glucose levels through tests like HBa1c.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of India HbA1c Market Research Report

Segment Analysis

The India HbA1c market has been segmented based product type, technology, application, and end user.

On the basis of product type, the India HbA1c market is segmented into reagents & kits, and instruments. Furthermore, the instrument segment bifurcated into benchtop devices and hand-held devices. Reagents and kits held the largest market with a market share of 62.73% in 2022, and instruments are anticipated to register the highest CAGR from 2022 to 2032. Reagents and kits are important products to run such tests and are needed every day. Rising incidences of type 2 diabetes and sickle cell disease boost the demand for HbA1c testing, which further increases the need for reagents and kits in hospitals, clinics, diagnostic centers, research, and laboratories.

Based on technology, the India HbA1c market is segmented into ion-exchange HPLC, immunoassay, boronate affinity HPLC, enzymatic assay, turbidimetric inhibition immunoassay (TINIA), and others. The immunoassay segment accounted for the largest market in 2022, and turbidimetric inhibition immunoassay (TINIA) is anticipated to be the fastest-growing for the forecast period of 2023–2032. Factors driving the growth of the technology segment are rising demand of accurate and reliable measurements of glycated hemoglobin levels, capillary electrophoresis offers high accuracy and precision in HbA1c measurements that will increase the demand., and growing need for advanced analytical techniques to enhance the accuracy and efficiency of diabetes.

On the basis of application, the India HbA1c market is segmented into thalassemia, sickle cell anemia, and type 2 diabetes. The type 2 diabetes segment accounted for the largest share in 2022 and was the fastest-growing segment during the forecast period due to the rise in obesity rates, which is a driver of type 2 diabetes; excess adiposity, particularly visceral fat, contributes to insulin resistance, a hallmark feature of type 2 diabetes; and increasing adoption of a sedentary lifestyle due to rapid urbanization.

Based on end user, the India HbA1c market is segmented into hospitals and clinics, diagnostic laboratories, and others. The hospitals and clinics segment accounted for the largest share in 2022, and the diagnostic laboratories segment is the fastest-growing segment during the forecast period. The drivers that are boosting the growth of the end user segment are diagnostic accuracy and reliability, rising adaption to integrated healthcare services, rising awareness regarding high accuracy, reliability, and consistency in results, and growing collaboration and partnerships with hospitals, social service organizations, and government agencies.

Key Findings of the Study

• The India HbA1c market is expected to reach USD 0.29 billion by 2032, at a CAGR of 8.49% during the forecast period.


• Based on technology, the immunoassay segment held the largest market with a market share of 46% in 2022 and turbidimetric inhibition immunoassay is the fastest-growing segment during the forecast period.


• Siemens Healthineers AG (Germany), PTS Diagnostics (US), ARKRAY, Inc (Japan), Abbott (US), Bio-Rad Laboratories, Inc (US), Transasia Bio-Medicals (India), F. Hoffmann-La Roche Ltd. (Switzerland), Beckman Coulter, Inc. (US), LumiraDx (UK), and HemoCue AB (Sweden) are the key players in the market.